title: New agents for Gram-positive bacteria.
abstract: Infections caused by multiple-resistant Gram-positive organisms continue to occur at an alarming rate worldwide. Two new and unique antimicrobial agents targeted specifically against such organisms, quinupristin/dalfopristin and linezolid, have been approved for use in the USA in the past year and will play an important role in the treatment of life-threatening infections. In addition, several new fluoroquinolones have been approved recently or will be available in the near future to aid in the treatment of infections caused by resistant strains of Streptococcus pneumoniae.
authors.affiliation: Clinical Pharmacokinetics Laboratory, Kaleida Health/Millard Fillmore Hospital and School of Pharmacy, State University of New York-Buffalo, NY, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Bhavnani
authors.forename: C H
authors.initials: CH
authors.lastname: Ballow
mesh_terms: D000081:Acetamides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D024841:Fluoroquinolones; D006020:Glycopeptides; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D000069349:Linezolid; D000077427:Lipoglycopeptides; D023303:Oxazolidinones / Q000627:therapeutic use; D014769:Virginiamycin / Q000031:analogs & derivatives; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D006020:Glycopeptides; D000069349:Linezolid; D000077427:Lipoglycopeptides; D023303:Oxazolidinones; D014769:Virginiamycin; C100708:oritavancin; D014640:Vancomycin